Cargando…
Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
Kidney transplant recipients administered belatacept‐based maintenance immunosuppression present with a more favorable metabolic profile, reduced incidence of de novo donor‐specific antibodies (DSAs), and improved renal function and long‐term patient/graft survival relative to individuals receiving...
Autores principales: | Kirk, Allan D., Adams, Andrew B., Durrbach, Antoine, Ford, Mandy L., Hildeman, David A., Larsen, Christian P., Vincenti, Flavio, Wojciechowski, David, Woodle, E. Steve |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246831/ https://www.ncbi.nlm.nih.gov/pubmed/33128812 http://dx.doi.org/10.1111/ajt.16386 |
Ejemplares similares
-
Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
por: Vincenti, F., et al.
Publicado: (2017) -
Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
por: Wojciechowski, David, et al.
Publicado: (2012) -
Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014) -
Belatacept: the challenges with transformational drugs
por: Vincenti, Flavio
Publicado: (2017) -
Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)